Aptevo Therapeutics to Present at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting
The posters will provide updates on APVO603, which is wholly owned by
The abstracts and the accompanying posters will be available in the Virtual Poster Hall to registered attendees from
Title: APVO603: Dual-targeting of 4-1BB and OX40 with an ADAPTIR bispecific antibody enhances anti-tumor responses to solid tumors
Summary: The data to be presented will highlight preclinical in vivo anti-tumor activity showing that APVO603 significantly reduces tumor burden in a murine bladder cancer model. APVO603 is shown to synergistically enhance CD4, CD8 T-cell and NK cells' cytotoxic potential when compared to either 4-1BB or OX40 monospecific antibodies alone or in combination. This was demonstrated in multiple in vitro studies showing increased effector cell proliferation, cytokine secretion, granzyme expression and tumor lysis. Lead cell clone has been identified, CMC activities have been initiated and pre-IND studies have begun. Current Preclinical and CMC activities support advancing the APVO603 program towards clinical development for the treatment of multiple solid tumors.
Details of the Oral Presentation:
During Session 208 (Bispecific Antibodies in Cancer Immunotherapy) on
Details of the Poster Presentation:
Live question and answer sessions will occur for the APVO603 poster (Number 633) on
Title: ALG.APV-527: Potent tumor-directed T cell activation and in vivo tumor inhibition induced by a 4-1BB x 5T4 ADAPTIR bispecific antibody
Summary: The poster will present preclinical data demonstrating that ALG.APV-527 has a favorable safety profile with no indication of systemic immune activation or liver toxicity in NHP or murine models. ALG.APV-527 induces robust in vitro killing of tumors that is dependent on 5T4 engagement. In vivo, ALG.APV-527 augmented anti-tumor responses and promoted tumor-specific memory. Clinical development is planned for ALG.APV-527 and CTA documents are prepared for filing of a phase 1 clinical trial in the
Details of the Poster Presentation:
Live question and answer sessions will occur for the ALG.APV-527 poster (Number 851) on
About
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding potential royalty and milestone payments, Aptevo's ability to successfully obtain revenue on terms acceptable to Aptevo, Aptevo's outlook, financial performance or financial condition, estimated cash burn, Aptevo's technology and related pipeline, collaboration and partnership opportunities, and any other statements containing the words "believes," "expects," "anticipates," "intends," "plans," "forecasts," "estimates," "will" and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; adverse developments in research and development; adverse developments in the
For Further Information:
Senior Director, Investor Relations and Corporate Communications
Phone: 206.859.6616
E-mail: IR@apvo.com
SOURCE:
accesswire.com
https://www.accesswire.com/615311/Aptevo-Therapeutics-to-Present-at-the-Society-for-Immunotherapy-of-Cancers-SITC-35th-Virtual-Annual-Meeting